9 result(s) for Sarcoma
| PI Name | Protocol # | Title |
|---|---|---|
| Lara Davis | IRB00012039 | Sarcoma Survivorship Registry |
| Lara Davis | STUDY00015649 | A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma |
| Christopher Ryan | STUDY00015989 | A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS) |
| Lara Davis | STUDY00016070 | A Phase 1B Study of Ribociclib in Combination with Doxorubicin in Advanced Soft Tissue Sarcomas |
| Kenneth Gundle | STUDY00017895 | Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage’s CIVO™ device in soft tissue sarcoma patients undergoing surgery. |
| Christopher Ryan | STUDY00018084 | [NCI CIRB] S1609, "DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS” |
| Lara Davis | STUDY00019313 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF) |
| Lara Davis | STUDY00019380 | An open-label, multi-institutional phase 0 study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate |
| Christopher Ryan | STUDY00019992 | [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH) |
You may also qualify for Phase 1 Program trials.